<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Targeted therapies for initial treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Targeted therapies for initial treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma</h1>
<div class="graphic"><div class="figure"><div class="ttl">Targeted therapies for initial treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma</div><div class="cntnt"><table cellspacing="0"><colgroup span="1" width="30%"></colgroup> <colgroup span="1" width="70%"></colgroup> <tbody> <tr> <td class="subtitle1">Regimen</td> <td class="subtitle1">Clinical considerations</td> </tr> <tr> <td> BTK inhibitor: <ul class="decimal_heading"> <li>Acalabrutinib</li> <li>Zanubrutinib</li> <li>Ibrutinib</li> </ul> </td> <td> <ul> <li>Oral medication.</li> <li>Administered as continuous therapy.</li> <li>Increases the risk for bleeding, atrial fibrillation, and hypertension.</li> <li>Other toxicities: fatigue, rash, infections, and myalgia/arthralgia.</li> <li>All are CYP3A4 substrates, contributing to numerous drug interactions; generally avoid with strong CYP3A4 inhibitors or inducers. Use with caution in patients on anticoagulation, especially warfarin.</li> <li>May be preferred over venetoclax plus obinutuzumab in patients with kidney impairment; kidney impairment increases the risk of TLS with venetoclax.</li> <li>Acalabrutinib and zanubrutinib are preferred over ibrutinib as they are at least as effective and better tolerated.</li> </ul> </td> </tr> <tr> <td>Venetoclax plus obinutuzumab</td> <td> <ul> <li>Combination of oral medication (venetoclax) and intravenous medication (obinutuzumab).</li> <li>Administered for a fixed duration (12 months).</li> <li>Allows for retreatment at the time of progression.</li> <li>Requires risk-based TLS prophylaxis and monitoring.</li> <li>Most common toxicities: neutropenia, thrombocytopenia, anemia, diarrhea, nausea, upper respiratory tract infection, cough, musculoskeletal pain, fatigue, and edema.</li> <li>Clinically significant TLS is rare with proper precautions.</li> <li>Avoided in patients on nephrotoxic drugs and those taking a strong CYP3A4 inhibitor, as both can increase the risk for TLS with venetoclax (a CYP3A4 substrate); also avoid use with moderate or strong CYP3A4 inducers.</li> <li>May be preferred over a BTK inhibitor in those with cardiovascular disorders, uncontrolled hypertension, and/or a high risk for bleeding.</li> <li>Cross-trial comparisons suggest decreased efficacy in patients with del17p or <em>TP53</em> mutation.</li> </ul> </td> </tr> <tr> <td>Ibrutinib plus venetoclax</td> <td> <ul> <li>All-oral regimen.</li> <li>Administered for a fixed duration (15 months).</li> <li>Allows for retreatment at the time of progression.</li> <li>Requires risk-based TLS prophylaxis and monitoring but is logistically easier than with venetoclax plus obinutuzumab.</li> <li>Most common toxicities: neutropenia, diarrhea, and hypertension.</li> <li>Clinically significant TLS is rare.</li> <li>Both are CYP3A4 substrates, contributing to numerous drug interactions; generally avoid in patients taking strong CYP3A4 inhibitors or moderate or strong CYP3A4 inducers.</li> <li>Less preferred in patients with conditions that make them poor candidates for a BTK inhibitor (eg, cardiovascular disorders, uncontrolled hypertension, and/or high risk for bleeding).</li> <li>Limited data in patients with del17p or <em>TP53</em> mutation.</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">Agents in this table are subject to significant drug interactions, requiring dose adjustment or avoidance. For more detailed information, refer to the <a href="https://www.uptodate.com/drug-interactions">Lexicomp drug interactions</a> program within UpToDate.</div><div class="graphic_footnotes">BTK: Bruton tyrosine kinase; TLS: tumor lysis syndrome.</div><div id="graphicVersion">Graphic 142941 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
